Mediobanca CEO Says Governments Are Hampering Bank Consolidation
Save
Mediobanca SpA Chief Executive Officer Alberto Nagel said that national governments are an obstacle to creating bigger banks in the European Union.
'I don't think it's going to help the consolidation' of the financial industry in the bloc, Nagel said Friday on Bloomberg TV, referring to efforts to slow or even prevent banking takeovers in Germany, Italy and Spain. That level of obstruction is a 'new factor,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Evonik Industries Second Quarter 2025 Earnings: Misses Expectations
Evonik Industries (ETR:EVK) Second Quarter 2025 Results Key Financial Results Revenue: €3.50b (down 11% from 2Q 2024). Net income: €120.0m (up from €5.00m loss in 2Q 2024). Profit margin: 3.4% (up from net loss in 2Q 2024). EPS: €0.26 (up from €0.011 loss in 2Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Evonik Industries Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 5.4%. Earnings per share (EPS) also missed analyst estimates by 31%. Looking ahead, revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany. Performance of the German Chemicals industry. The company's shares are down 9.6% from a week ago. Risk Analysis Be aware that Evonik Industries is showing 2 warning signs in our investment analysis and 1 of those is significant... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
MEDICLIN Second Quarter 2025 Earnings: EPS: €0.20 (vs €0.04 in 2Q 2024)
MEDICLIN (ETR:MED) Second Quarter 2025 Results Key Financial Results Revenue: €203.4m (up 8.6% from 2Q 2024). Net income: €9.88m (up 395% from 2Q 2024). Profit margin: 4.9% (up from 1.1% in 2Q 2024). The increase in margin was driven by higher revenue. EPS: €0.20 (up from €0.04 in 2Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period MEDICLIN Earnings Insights Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 4.0% growth forecast for the Healthcare industry in Germany. Performance of the German Healthcare industry. The company's shares are up 2.0% from a week ago. Risk Analysis We don't want to rain on the parade too much, but we did also find 1 warning sign for MEDICLIN that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Symrise First Half 2025 Earnings: Revenues Disappoint
Symrise (ETR:SY1) First Half 2025 Results Key Financial Results Revenue: €2.55b (flat on 1H 2024). Net income: €268.2m (up 12% from 1H 2024). Profit margin: 11% (up from 9.3% in 1H 2024). EPS: €1.92 (up from €1.71 in 1H 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Symrise Revenues Disappoint Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) was mostly in line with analyst estimates. Looking ahead, revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Germany. Performance of the German Chemicals industry. The company's shares are down 10% from a week ago. Risk Analysis Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Symrise that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
